John McHutchison, Assembly Biosciences CEO (Getty Images)

As­sem­bly Bio's he­pati­tis B pro­gram flops as a po­ten­tial cure in PhII, send­ing shares spi­ral­ing

Look­ing for a he­pati­tis B cure, As­sem­bly Bio­sciences $ASMB has struck out in a Phase II.

The South San Fran­cis­co-based com­pa­ny an­nounced Thurs­day af­ter­noon that its lead ex­per­i­men­tal drug ve­bi­corvir, in com­bi­na­tion with nu­cle­o­side ther­a­py, could not keep pa­tients dis­ease-free af­ter stop­ping treat­ments. In to­tal, 39 of the 41 in­di­vid­u­als in the open-la­bel study re­lapsed, as the reg­i­men failed to achieve a mean­ing­ful sus­tained vi­ro­log­ic re­sponse.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.